Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/wnan.119 http://scihub22266oqcxt.onion/10.1002/wnan.119 20872839!7169818!20872839     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20872839&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Wiley+Interdiscip+Rev+Nanomed+Nanobiotechnol 2011 ; 3 (2): 174-196 Nephropedia Template TP {{tp|p=20872839|t=2011. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design |pdf=|usr=}}{{20872839}} gab.com Text Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design JO: Wiley Interdiscip Rev Nanomed Nanobiotechnol http://www.kidney.de/pget.php?&tw=1&pmid=20872839 #FOAvip Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus-like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the genetic material required for replication, promote immunogenicity and have been developed and approved as vaccines in some cases. In addition, many of these VLPs can be used as molecular platforms for genetic fusion or chemical attachment of heterologous antigenic epitopes. This approach has been shown to provide protective immunity against the foreign epitopes in many cases. A variety of VLPs and virus-based nanoparticles are being developed for use as vaccines and epitope platforms. These particles have the potential to increase efficacy of current vaccines as well as treat diseases for which no effective vaccines are available. Twit Text FOAVip Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design ????Wiley Interdiscip Rev Nanomed Nanobiotechnol http://www.kidney.de/pget.php?&tw=1&pmid=20872839 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20872839 #FOAvip English Wikipedia <ref>{{Cite pmid|20872839}}</ref> Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design #MMPMID20872839 Plummer EM; Manchester M Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011[Mar]; 3 (2): 174-196 PMID20872839show ga Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus-like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the genetic material required for replication, promote immunogenicity and have been developed and approved as vaccines in some cases. In addition, many of these VLPs can be used as molecular platforms for genetic fusion or chemical attachment of heterologous antigenic epitopes. This approach has been shown to provide protective immunity against the foreign epitopes in many cases. A variety of VLPs and virus-based nanoparticles are being developed for use as vaccines and epitope platforms. These particles have the potential to increase efficacy of current vaccines as well as treat diseases for which no effective vaccines are available. |Animals[MESH] |Humans[MESH] |Nanomedicine/*methods[MESH] |Nanoparticles/*chemistry[MESH] |Viral Vaccines/*chemistry/*immunology[MESH] |Virion/chemistry/*immunology[MESH]Viral nanoparticles and virus-like particles: platforms for contempora(epmc).pdf DeepDyve Pubget Overpricing